Blagoveschensk, Russian Federation
Blagoveschensk, Blagoveshchensk, Russian Federation
At present time chronic obstructive pulmonary disease (COPD) is considered to be an airway disease with respiratory and systemic manifestations. Cardiovascular diseases have the largest influence on COPD severity among numerous coexisting diseases. These diseases are united together with such pathogenic factors as a sedentary lifestyle, disorder of lipid metabolism and hemostasis, endothelial dysfunction. Tissue hypoxia, oxidative stress, endothelial dysfunction, activation of neurohumoral systems, disorder of water-electrolyte metabolism, and also chronic systemic inflammation are the basic pathogenetic mechanisms of development of the coexisting cardiac pathology of patients with COPD. At the same time the regularities of changing of the clinical picture, peculiarities of a disease course, and also outcomes of COPD in case of comorbidity are still insufficiently studied. Today the main attention is focused on the introduction of noninvasive methods of diagnose of vessels’ elastic properties into clinical practice. Stiffness (rigidity) of the arterial wall studied through the use of the volume sphygmography method is considered to be one of the informative markers of cardiovascular morbidity and mortality. Pulse wave velocity depends on the stiffness of the vessel wall: the higher the vessel’s stiffness is, the thicker the vessel’s wall is and the smaller its diameter is, then the faster the pulse wave velocity is. An early disease detection of changings of arterial stiffness and metabolic disorders has an important clinic and prognostic value and makes it possible to coordinate therapy timely with the combined cardiopulmonary pathology and avert negative consequences of hemodynamic complications.
chronic obstructive pulmonary disease, arterial stiffness, cardiopulmonary pathology, systemic inflammation, oxidative stress, comorbidity
1. Avdeev S.N. Chronic obstructive pulmonary disease. Guide for practicing physicians. Moscow: Atmosfera; 2010. 240 (in Russian).
2. Avdeev S.N. Is it possible to improve prognosis in patients with chronic obstructive pulmonary disease? Russian Pulmonology 2015; 25(4):469–476 (in Russian). doi: 10.18093/0869-0189-2015-25-4-469-476
3. Avdeev S.N. COPD as a systemic disease. Pulmonologiya 2007; (2):104–116 (in Russian).
4. Aksenova T.A., Gorbunov V.V., Pakhomenko Yu.V. 24-hour monitoring central aortic pressure in patients with hypertensive disease and concomitant chronic obstructive pulmonary disease. Klin. Med. (Mosk.) 2013; 91(7):43–47 (in Russian).
5. Brodskaya T.A., Geltʹzer B.I., Nevzorova V.A., Motkina E.V. Arterial and myocardial rigidity in patients with chronic obstructive pulmonary disease. Kazan medical journal 2008; 89(5):642–647 (in Russian).
6. Budnevskiy A.V., Chernov A.V., Isaeva Y.V., Malysh E.Y. Clinical efficacy of pulmonary rehabilitation program in patients with chronic obstructive pulmonary disease and metabolic syndrome. Russian Pulmonology 2015; 25(4):447–455 (in Russian). doi: http://dx.doi.org/10.18093/0869-0189-2015-25-4-447-455
7. Gaynitdinova V.V., Avdeev S.N. Large peripheral vessel remodeling in patients with chronic obstructive pulmonary disease and in hypertension co-morbidity. Russian Pulmonology 2015; 25(1):50–57 (in Russian). doi: 10.18093/0869-0189-2015-25-1-50-57
8. Gajnitdinova V.V., Bakirov A.B., Akhmetzyanova E.Kh., Berdikaeva N.F., Zakirova V.B. Arterial stiffness of peripheral vasculature in patients with chronic obstructive pulmonary disease and its association with arterial hypertension. Kazan medical journal 2013; 94(6):808–812 (in Russian).
9. Ignatova G.L., Antonov V.N., Rodionova O.V. Dysfunction of external respiration during combined course of chronic obstructive pulmonary disease and ischemic heart disease. Consilium Medicum 2014; 16(11):28–32 (in Russian).
10. Karoli N.A., Dolishnya G.R., Rebrov A.P. Arterial rigidity in patients with chronic obstructive pulmonary disease. Klin. Med. (Mosk.) 2012. №9. C.38–42 (in Russian).
11. Kulik E.G., Pavlenko V.I., Naryshkina S.V. Arterial stiffness and markers of endothelial dysfunction during chronic obstructive pulmonary disease. In: Proceedings of the VII conference of pulmonologists of Siberia and Far East. Blagoveshchensk; 2017:155–158 (in Russian).
12. Kulik E.G., Pavlenko V.I., Naryshkina S.V. Von Willebrand factor and vascular endothelial dysfunction in patients with chronic obstructive pulmonary disease. Amurskiy meditsinskiy zhurnal 2017; 1:41−43 (in Russian).
13. Leshchenko I.V., Baranova I.I. Inflammatory biomarkers in chronic obstructive pulmonary disease. Russian Pulmonology 2012; (2):108–117 (in Russian). doi:10.18093/0869-0189-2012-0-2-108-117
14. Makarova M.A., Avdeev S.N. Arterial wall stiffness and endothelial dysfunction in patients with chronic obstructive pulmonary disease. Russian Pulmonology 2011; (4):109–117 (in Russian). doi: 10.18093/0869-0189-2011-0-4-109-117
15. Makarova M.A., Avdeev S.N., Chuchalin A.G. Hypoxemia as a potential risk factor of endothelial dysfunction and arterial stiffness in patients with chronic obstructive pulmonary disease. Russian Pulmonology 2013; (3):36–40 (in Russian). doi: 10.18093/0869-0189-2013-0-3-36-40
16. Mamaeva M.G., Sobko E.A., Kraposhina A.Y., Solov'eva I.A., Logacheva N.S., Eydemiller N.S., Kuz'minova T.N., Salmina A.B., Demko I.V. Clinical and pathogenic aspects of arterial stiffness and the left heart remodeling in patients with chronic obstructive pulmonary disease and coronary artery disease. Russian Pulmonology 2014; (5):5–10 (in Russian). doi: 10.18093/0869-0189-2014-0-5-5-10
17. Ovcharenko S.I. Chronic obstructive pulmonary disease and arterial hypertension (review). Consilium medicum 2012; 11:51–55 (in Russian).
18. Ovcharenko S.I., Nersesyan Z.N. Management of patients with chronic obstructive pulmonary disease combined with arterial hypertension. Consilium medicum 2013; 12:17–26 (in Russian).
19. Ovcharenko S.I. Diagnosis of chronic obstructive pulmonary disease. Consilium medicum 2014; 16(12):17–26 (in Russian).
20. Ovcharenko S.I., Galetskayte Ya.K. Roflumilast in treatment of patients suffering from obstructive chronic pulmonary disease of severe clinical course with polymorbid pathology. Lechashchiy vrach 2015; 5:74–78 (in Russian).
21. Otteva E.N., Klinkova E.V., Garbuzova O.G., Isakova V.N., Bandurko E.V. Arterial rigidity, a marker of cardiovascular diseases. Klin. Med. (Mosk.) 2012; 90(1):4–12 (in Russian).
22. Pavlenko V.I., Kolosov V.P., Naryshkina S.V. Features of comorbide course of chronic obstructive pulmonary disease and coronary heart disease, and their prognosis and treatment. Blagoveshchensk; 2014 (in Russian).
23. Pavlenko V.I., Naryshkina S.V. Assessment of the degree of influence of cardiovascular factors risk on stiffness of the vascular wall in patients with combined cardiopulmonary diseases. In: Proceedings of the XI International Scientific Conference "System Analysis in Medicine". Blagoveshchensk; 2017: 107−110 (in Russian).
24. Pavlenko V.I., Naryshkina S.V. Clinical and functional course of chronic obstructive pulmonary disease associated with ischemic heart disease against the complex therapy with Nebivolol. Bûlleten' fiziologii i patologii dyhaniâ 2012; 43:34–39 (in Russian).
25. Kalinkina O.B. Impact of body mass decrease of patients with metabolic syndrome on cardiovascular risk factors and reproductive function. Obesity and metabolism 2015; 12(2):14–18 (in Russian). doi: 10.14341/OMET2015214-18
26. Skotnikov A.S., Dokhova O.M., Shulgina E.S. Systemic inflammation and complications of ”vascular" comorbidity in patients with COPD. The Russian Archives of Internal Medicine 2015; (5):49–54 (in Russian). doi: 10.20514/2226-6704-2015-0-5-49-54
27. Skotnikov A.S., Dokhova O.M., Shulgina E.S. Role of COPD in development and progressing of comorbidity. Lechashchiy vrach 2015; (10):17–20 (in Russian).
28. Statsenko M.E., Shilina N.N., Vinnikova A.A. Organoprotective and metabolic effects of taurine in the treatment of patients with chronic heart failure and diabetes mellitus type 2. Consilium medicum 2014; 16(4):40–45 (in Russian).
29. Tanchenko O.A., Naryshkina S.V., Sivyakova O.N. Ursodeoxycholic acid in complex treatment of metabolic syndrome. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2012; 22(1):82–86 (in Russian).
30. Tanchenko O.A., Naryshkina S.V., Reshetnikova L.K. Peculiarities of immune status in patients with metabolic syndrome. Dal'nevostochnyy meditsinskiy zhurnal 2014; 2:20–23 (in Russian).
31. Troitskaya E.A., Starostina E.S., Kobalava Zh.D. Prevalence rate of surrogate markers of atherosclerosis and arterial rigidity of patients with type 2 diabetes mellitus and arterial hypertension. Klinicheskaya farmakologiya i terapiya 2017; 26(4):34–38 (in Russian).
32. Chuchalin A.G., Tseymakh I.Y., Momot A.P., Mamaev A.N., Karbyshev I.A., Kostyuchenko G.I. Changes in systemic inflammatory and hemostatic response in patients with co-morbidity of exacerbation of chronic obstructive pulmonary disease, chronic heart failure and obesity. Russian Pulmonology 2014; 24(6):25–32 (in Russian). doi: 10.18093/0869-0189-2014-0-6-25-32
33. Anthonisen N.R., Connett J.E., Enright P.L., Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am. J. Respir. Crit. Care Med. 2002; 166(3):333–339.
34. Bateman E., Calverley P.M., Fabbri L., Rabe K.F., Rennard S.I., Martinez F. J., Goehring U-M. Efficacy of roflumilast in patients with a history of frequent exacerbations: Pooled data from pivotal 12-month studies. Eur. Respir. J. 2010; 36(Suppl.54):718s–719s.
35. Calverley P.M., Sanchez-Toril F., McIvor A., Teichmann P., Bredenbroeker D., Fabbri L.M. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2013; 176(2):154–161.
36. Claessen H., Brenner H., Drath C., Arndt V. Repeated measures of body mass index and risk of health related outcomes. Eur. J. Epidemiol. 2012; 27(3):215–224.
37. Clini E., Crisafulli E., Radaeli A., Malerba M. COPD and the metabolic syndrome: an intriguing association. Intern. Emerg. Med. 2013; 8(4):283–289.
38. Decramer M., Celli B., Kesten S., Lystig T., Mehra S., Tashkin D.P. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease: a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374(9696):1171–1178.
39. Dodd J.W., Hogg L., Nolan J., Jefford H., Grant A., Lord V.M., Falzon C., Garrod R., Lee C., Polkey M.I., Jones P.W., Man W.D., Hopkinson N.S. The COPD Assessment Test (CAT): response to pulmonary rehabilitation. A multicenter, prospective study. Thorax 2011; 66(5):425–429.
40. Drummond M.B., Dasenbrook E.C., Pitz M.W., Murphy D.J., Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2011; 300(20):2407–2416.
41. Eisner M. D., Blanc P. D., Sidney S., Yelin E. H., Lathon P. V., Katz P. P., Tolstykh I., Ackerson L., Iribarren C. Body composition and functional limitation in COPD. Respir. Res. 2007; 8(1):7–15.
42. Eze I.C., Schaffner E., Zemp E., von Eckardstein A., Turk A., Bettschart R., Schindler C., Probst-Hensch N. Environmental tobacco smoke exposure and diabetes in adult never-smokers. Environ. Health 2014; 13:74.
43. Grootendorst D.C., Gauw S.A., Verhoosel R.M., Sterk P.J., Hospers J.J., Bredenbröker D., Bethke T.D., Hiemstra P.S., Rabe K.F. Reduction in sputum neutrophils and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007; 62(12):1081–1087.
44. Groenewegen K.H., Schols A.M., Wouters E.F. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124(2):459–467.
45. Fortier C., Agharazii M. Arterial stiffness gradient. Pulse (Basel) 2015; 3(3-4):159–166.
46. Loscalzo J. Systems biology and personalized medicine: a network approach to human disease. Proc. Am. Thorac. Soc. 2011; 8(2):196–198.
47. Maclay J.D., McAllister D.A., Mills N.L., Paterson F.P., Ludlam C.A., Drost E.M., Newby D.E., Macnee W. Vascular dysfunction in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180(6):513–520.
48. Niranen T.J., Kalesan B., Larson M.G., Hamburg N.M., Benjamin E.J., Mitchell G.F., Vasan R.S. Aortic-brachial arterial stiffness gradient and cardiovascular risk in the community: The Framingham Heart Study. Hypertension 2017; 69(6):1022–1028.
49. Rabe K.F., Bateman E.D., Donnell D. Witte S., Bredenbröker D., Bethke T.D. Roflumilast an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366(9485):563–571.
50. Schols A.M., Broekhuizen R., Weling-Scheepers C.A., Wouters E.F. Body composition and mortality in chronic obstructive pulmonary disease. Am. J. Clin. Nutr. 2005; 82(1):53–59.
51. Thomsen M., Dahl M., Lange P., Vestbo J., Nordestgaard B.G. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012; 186(10):982–988.
52. Wedzicha J.A., Seemungal T.A. COPD exacerbations: defining their cause and prevention. Lancet. 2007; 370(9589):786–796.
53. Wells C.E, Baker EH. Metabolic syndrome and diabetes mellitus in COPD. In: Rabe K.F., Wedzicha J.A., Wouters E.F.M. (eds). COPD and Comorbidity. European Respiratory Society, Sheffield; 2013:117–134. doi: 10.1183/1025448x.erm5913